ClinicalTrials.Veeva

Menu
L

Latin Clinical Trial Center | San Juan, PR

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3526318
LY3556050
LY3857210
LY3298176
Tirzepatide
LY3016859
Maridebart Cafraglutide
EDP-305
LY3437943
Lorundrostat

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

18 of 57 total trials

A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)

The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Rese...

Active, not recruiting
Nonalcoholic Fatty Liver Disease
Fatty Liver, Nonalcoholic
Drug: Semaglutide
Drug: Placebo

The purpose of the chronic pain master protocol is to compare independent pain interventions and establish an overarching structure for the disease-s...

Enrolling
Chronic Low-back Pain
Diabetic Neuropathic Pain
Drug: LY3016859 ISA
Drug: Placebo Oral

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic...

Enrolling
Metabolic Dysfunction-associated Steatohepatitis (MASH)
Drug: Placebo
Drug: ALN-HSD

A study evaluating the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GLPG3667 administered orally once daily fo...

Active, not recruiting
Systemic Lupus Erythematosus
Drug: GLPG3667
Drug: Placebo

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The main purpose of this study is to assess the dose-response relationship of maridebart cafraglutide on glucose control compared with placebo.

Enrolling
Type 2 Diabetes Mellitus (T2DM)
Drug: Maridebart Cafraglutide
Drug: Placebo

This study aims to examine the efficacy and safety of obexelimab in participants with systemic lupus erythematosus (SLE).

Enrolling
Systemic Lupus Erythematosus
Drug: Placebo
Drug: Obexelimab

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes a...

Active, not recruiting
Type 2 Diabetes
Drug: Semaglutide
Drug: Orforglipron

The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiov...

Active, not recruiting
Obesity
Cardiovascular Diseases
Drug: Retatrutide
Drug: Placebo

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Drug: Maridebart cafraglutide
Drug: Placebo

This is a phase 3, randomized, placebo-controlled study of the efficacy and safety of enlicitide decanoate, an oral proprotein convertase subtilisin/...

Enrolling
Arteriosclerosis
Hypercholesterolaemia
Drug: Placebo
Drug: Enlicitide Decanoate
Locations recently updated

The primary objective of this study is to demonstrate that maridebart cafraglutide is superior to placebo for percent change in body weight.

Enrolling
Obesity
Drug: Placebo
Drug: Maridebart Cafraglutide

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis
Drug: Survodutide
Drug: Placebo matching survodutide
Locations recently updated

This study is open to adults who are at least 18 years old and have:* a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Drug: Survodutide
Drug: Placebo

Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarse...

Enrolling
Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
Drug: TQJ230
Drug: Placebo

This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with hypert...

Invitation-only
Hypertension
Drug: lorundrostat
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

Trial sponsors

Lilly logo
Amgen logo
Boehringer Ingelheim logo
Enanta Pharmaceuticals logo
I
Merck Sharp & Dohme (MSD) logo
M
Novartis logo
Pfizer logo
Regeneron Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems